KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.

Matthew R Smith, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Marie-Aude Le Berre, Ateesha F Mohamed, Dawn Odom, Jennifer Bartsch, Amir Snapir, Toni Sarapohja, Karim Fizazi

Eur J Cancer 154 138-146

PMID34273811
PMCID-
DOI10.1016/j.ejca.2021.06.010
发表日期2021-07-17
入排依据:This is an analysis of health-related quality of life outcomes from the ARAMIS trial. While the parent trial was a Phase III randomized trial with a drug intervention and MFS/OS as primary/key secondary endpoints, this specific report focuses solely on patient-reported quality-of-life endpoints (time to deterioration on FACT-P and EORTC QLQ-PR25). It is therefore a quality-of-life analysis and does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint for inclusion.
摘要

摘要

BACKGROUND: In the ARAMIS trial, darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT significantly improved metastasis-free survival (MFS), overall survival (OS) and time to pain progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Herein, we present analyses of patient-reported health-related quality of life (HRQoL) outcomes. PATIENTS AND METHODS: This double-blind, placebo-controlled, phase III trial randomised patients with nmCRPC and prostate-specific antigen doubling time ≤10 months to darolutamide 600 mg (n = 955) twice daily or matched placebo (n = 554) while continuing ADT. The primary end-point was MFS; the secondary end-points included OS and time to pain progression. In this analysis, HRQoL was assessed by the time to deterioration using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) prostate cancer subscale (PCS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Prostate Cancer Module (EORTC QLQ-PR25) subscales. RESULTS: Darolutamide significantly prolonged time to deterioration of FACT-P PCS versus placebo (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.70-0.91; P = 0.0005) at the primary analysis (cut-off date: 3rd September 2018). Time to deterioration of EORTC QLQ-PR25 outcomes showed statistically significant delays with darolutamide versus placebo for urinary (HR 0.64, 95% CI 0.54-0.76; P < 0.0001) and bowel (HR 0.78, 95% CI 0.66-0.92; P = 0.0027) symptoms. Time to worsening of hormonal treatment-related symptoms was similar between the two groups. CONCLUSION: In patients with nmCRPC who are generally asymptomatic, darolutamide maintained HRQoL by significantly delaying time to deterioration of prostate cancer-specific quality of life and disease-related symptoms versus placebo.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。